- £5m to £10m
- Medical, Miscellaneous
- UK Wide, Outside UK
- 28 November 2019
An innovative and progressive clinical trial supply company, offering fast, accurate and reliable pharmaceutical supply to its high-value client base.
Strategically sources commercial pharmaceutical medicines for all stages of clinical trials, supplying blue-chip companies on a global scale.
Positioned within both the US and China markets to achieve significant growth.
Our clients are offering the company for sale to seek additional investment.
- Fully licenced to supply pharmaceuticals within the US – the largest single market for clinical trials globally – having significant strategic advantage by partnering with one of the top two ADR’s (Authorised Distributors of Record) within the territory.
- Developed strategic and operational relationships within China, and is in a prime position to expand significantly into this territory.
Has 25 active clients, with 90% providing ongoing, reliable revenue.
Licenced by the UK Medicines and Healthcare Regulatory Agency (MHRA) and adheres with the EU’s guidelines for good distribution practice (GDP).
Operates out of registered offices both within the UK and US.
||Adjusted EBITDA (£'000)
- Turnover of £9.8m in YE19 with an adjusted EBITDA of £485k.
- Projected turnover of £21.7m in YE20, increasing to £43.2m in YE21 and £69m in YE22.
Gross profit increasing year-on-year and is set to reach £8m in YE22.